Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Mayer Highlights the Potential of TAS-102 in CRC

June 8th 2015

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dr. Manish Shah on the METGastric Study

June 4th 2015

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Study Opens Door for Nivolumab in HCC

May 29th 2015

Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Adjuvant and Combination Therapies for HCC

May 28th 2015

New Approaches in Hepatocellular Carcinoma

May 28th 2015

Genetic Testing and Second-Line Treatments in HCC

May 28th 2015

Administering Sorafenib in Hepatocellular Carcinoma

May 28th 2015

Multidisciplinary Systemic Therapy in HCC

May 28th 2015

Embolization Therapy for Unresectable HCC

May 28th 2015

Transplantation Versus Resection in Patients With HCC

May 28th 2015

The Impact of Cirrhosis on Treating HCC

May 28th 2015

HCC: Evolving Screening and Surveillance

May 28th 2015

Tabernero Discusses Novel Antibody Mixture Sym004 and Emerging Trends in Colorectal Cancer

May 18th 2015

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Fuchs Discusses Impact of Ramucirumab Approval in mCRC

May 15th 2015

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

TAS-102 Improves Survival in Refractory mCRC

May 15th 2015

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Initiative Seeks to Advance Molecular Understanding of Pancreatic Cancer

May 7th 2015

A partnership between the Pancreatic Cancer Action Network and Perthera, a self-described "concierge" for molecular diagnostic testing, is aiming to give patients with this hard-to-treat cancer the ability to determine the best course of treatment.

Dr. Andrew Chan on Aspirin's Link to Reduced Cancer Risk

May 4th 2015

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More

May 2nd 2015